You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

CLINICAL TRIALS PROFILE FOR DENILEUKIN DIFTITOX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for denileukin diftitox

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006345 ↗ Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma Completed Ligand Pharmaceuticals Phase 2 1999-11-01 RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.
NCT00023530 ↗ Blood and Marrow Transplant Clinical Research Network Completed Blood and Marrow Transplant Clinical Trials Network N/A 2001-09-01 The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.
NCT00023530 ↗ Blood and Marrow Transplant Clinical Research Network Completed National Heart, Lung, and Blood Institute (NHLBI) N/A 2001-09-01 The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.
NCT00050999 ↗ Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed Eisai Inc. Phase 4 1995-06-01 The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.
NCT00051012 ↗ Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed Eisai Inc. Phase 4 1995-09-01 The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also designed to determine the effectiveness of ONTAK in Cutaneous T-cell Lymphoma (CTCL) patients whose tumors do not express CD25.
NCT00051025 ↗ Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) Completed Eisai Inc. Phase 2 2000-05-01 The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for denileukin diftitox

Condition Name

Condition Name for denileukin diftitox
Intervention Trials
Epithelial Ovarian Cancer 3
Graft vs Host Disease 3
Lymphoma, T-Cell, Cutaneous 3
Sezary Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for denileukin diftitox
Intervention Trials
Lymphoma 10
Lymphoma, T-Cell 7
Carcinoma, Ovarian Epithelial 4
Leukemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for denileukin diftitox

Trials by Country

Trials by Country for denileukin diftitox
Location Trials
United States 136
Australia 7
Canada 7
Brazil 4
Poland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for denileukin diftitox
Location Trials
Texas 14
California 8
Pennsylvania 8
New York 8
Missouri 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for denileukin diftitox

Clinical Trial Phase

Clinical Trial Phase for denileukin diftitox
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 18
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for denileukin diftitox
Clinical Trial Phase Trials
Completed 17
Terminated 6
Withdrawn 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for denileukin diftitox

Sponsor Name

Sponsor Name for denileukin diftitox
Sponsor Trials
Eisai Inc. 12
National Cancer Institute (NCI) 4
University of Louisville 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for denileukin diftitox
Sponsor Trials
Other 36
Industry 16
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.